Effective for Treatment Upon Relapse of Low-Grade or Follicular Non-Hodgkin's Lymphoma (NHL)
The Goal of RITUXAN Upon Relapse: Control Low-Grade or Follicular Non-Hodgkin's Lymphoma
If there is a relapse, RITUXAN may be used alone for either 4 or 8 weekly treatments.
For many patients, taking RITUXAN helps control their low-grade or follicular non-Hodgkin's lymphoma upon relapse. That means a reduction in tumor size—even in those with large tumors and those who were treated with RITUXAN earlier in the course of their non-Hodgkin's lymphoma. This response lasted an average of 1 year for patients who were receiving RITUXAN. And for many patients who had responded to RITUXAN upon relapse, the response lasted even longer when they were treated with RITUXAN again.
Remember that results may be different for different people. Read the Medication Guide for a summary of the most important information about RITUXAN. Be sure to ask your oncologist which treatment options are right for you.
RITUXAN was tested as a treatment for relapsed low-grade or follicular NHL in 2 large studies. All patients in the studies received RITUXAN therapy.
The studies showed that, for many patients, RITUXAN helped control relapsed low-grade or follicular NHL. That means, for many patients, tumors shrunk significantly.
RITUXAN® is indicated for the treatment of patients with relapsed or refractory, low-grade or follicular, CD20-positive, B-cell NHL as a single agent
INDICATIONS
RITUXAN® (rituximab) is indicated for the treatment of patients with:
- Relapsed or refractory, low-grade or follicular, CD20-positive, B-cell NHL as a single agent
- Previously untreated follicular, CD20-positive, B-cell NHL in combination with CVP chemotherapy
- Non-progressing (including stable disease), low-grade, CD20-positive B-cell NHL, as a single agent, after first-line CVP chemotherapy
- Previously untreated diffuse large B-cell, CD20-positive NHL in combination with CHOP or other anthracycline-based chemotherapy regimens
IMPORTANT SAFETY INFORMATION
RITUXAN can cause serious side effects, some of which can be life-threatening, including: Progressive Multifocal Leukoencephalopathy (PML), infusion reactions, Tumor Lysis Syndrome (TLS), and severe skin reactions. Other serious and life-threatening side effects with RITUXAN include: hepatitis B virus reactivation, heart problems, infections, and stomach and bowel problems. Common side effects during RITUXAN infusions include: fever, headache, chills and shakes, nausea, itching, hives, cough, sneezing, and throat irritation or tightness.
Tell your doctor about any side effects that bother you or that do not go away. These are not all of the possible side effects with RITUXAN. Ask your doctor for more information.
Please read the Medication Guide in HTML or PDF versions for more information.
